{
    "nct_id": "NCT03398148",
    "official_title": "A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Ulcerative Colitis",
    "inclusion_criteria": "* Male or female aged >=18 to <= 80 years at the Baseline Visit. Where locally permissible, subjects 16 to < 18 years of age who meet the definition of Tanner stage 5 for development at the Baseline Visit.\n* Confirmed diagnosis of ulcerative colitis (UC) for at least 3 months prior to Baseline.\n* Active UC as assessed by Adapted Mayo Score and Endoscopic Subscore.\n* Demonstrated intolerance or inadequate response to conventional therapy and tofacitinib (not a biologic) and one or more biologic therapies.\n* Females must be postmenopausal for more than 1 year or surgically sterile or practicing specific forms of birth control.\nHealthy volunteers allowed\nMust have minimum age of 16 Years\nMust have maximum age of 80 Years",
    "exclusion_criteria": "* Participant with a current diagnosis of Crohn's disease (CD), inflammatory bowel disease-unclassified (IBD-U) or a history of radiation colitis or ischemic colitis.\n* Participant receiving prohibited medications and treatment.\n* Extent of inflammatory disease limited to the rectum as assessed by screening endoscopy.\n* Participant with currently known complications of UC (e.g., megacolon).\n* No known active Coronavirus Disease - 2019 (COVID-19) infection.",
    "miscellaneous_criteria": ""
}